As already suggested by several studies [33], [36]–[39], the use of CCR5 antagonist such as maraviroc, should be safe in patients with HIV and chronic hepatitis C, at least as far as liver histology and the efficacy of anti-HCV treatment are concerned. This evidence concerns the gene CCR5 and chronic hepatitis C virus infection.